Interleukin-6 is synergistically induced in Kaposi's sarcoma cells by interleukin-1 beta and double-stranded RNA (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Interleukin-6 is synergistically induced in Kaposi's sarcoma cells by interleukin-1 beta and double-stranded RNA (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 34:A2628 1993. Unique Identifier : AIDSLINE ICDB/94693569
Yang J; Offermann MK; Emory Univ., Atlanta, GA 30322

Abstract: Interleukin-6 (IL-6) is a multifunctional cytokine that functions as an autocrine growth factor for AIDS-derived Kaposi's sarcoma (KS) cells. Although some KS cells in culture have been reported to express constitutively high levels of IL-6, we find variability in the levels of IL-6 expressed by KS cells isolated from different patients (pts). In addition, IL-6 was highly inducible in all pts examined. KS cells derived from several different pts expressed low basal levels of IL-6. Incubation with either tumor necrosis factor alpha or lipopolysaccharide-induced secretion of IL-6, leading to levels that were 40- to 70-fold higher than in the uninduced state. Both IL-1 beta and the synthetic double-stranded RNA, poly (I:C), induced levels that were 100- to 200-fold above baseline. Dramatically, the combination of IL-1 beta and poly (I:C) led to a synergistic increase in IL-6 production with levels that were more than 500-fold higher than in the basal state. This suggests that in vivo situations in which KS cells encounter both IL-1 beta and double-stranded RNA would lead to high levels of IL-6 production and hence autocrine induction of KS cells. Such situations would exist in response to a number of viral infections and could explain the exacerbations of KS that occur during some systemic infections.

Keywords: Human Interleukin-1/*PHARMACOLOGY Interleukin-6/*BIOSYNTHESIS/METABOLISM Lipopolysaccharides Poly I-C/PHARMACOLOGY RNA, Double-Stranded/*PHARMACOLOGY Sarcoma, Kaposi's/*METABOLISM Tumor Cells, Cultured ABSTRACT
940228
M9420831

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .